Trestle Biotherapeutics

Trestle Biotherapeutics tackled end-stage renal disease, where 2 million patients worldwide depend on dialysis—a grueling treatment requiring three sessions weekly, each lasting four hours. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Patients experienced severe quality-of-life degradation: restricted diets, fluid limitations, fatigue, and shortened lifespans averaging five to ten years shorter than healthy individuals. The problem was acutely measurable through dialysis dependency rates, mortality statistics, and patient-reported outcomes showing depression and social isolation. Existing alternatives were limited: kidney transplantation offered the best outcome but faced severe donor shortages with only 20,000 transplants annually against 100,000+ patients waiting. Dialysis itself merely prolonged life without restoring function. Early validation emerged from clinical data demonstrating that even partial kidney function restoration dramatically improved patient outcomes and quality of life. Nephrologists universally acknowledged the unmet need, and patient advocacy groups actively sought alternatives. The regulatory pathway for regenerative medicine showed increasing FDA receptiveness to tissue-engineered solutions, signaling market readiness for innovative approaches beyond traditional transplantation.